TuHURA Biosciences, Inc./NV — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
TuHURA Biosciences (market cap ~$111M) announced a $50 million term credit facility from its largest shareholder in April 2026, bearing 12% annual interest with 5-year maturity (April 2031). The company has drawn $5.7M to date ($2.15M after June 30, 2026) and holds $1.0M cash at Q2 2026 quarter-end. The facility extends runway into 2028 and supports Phase 1b/2 trials for TBS-2025 (VISTA inhibitor in AML) and ongoing Phase 3 development of IFx-2.0 (innate immune agonist for Merkel cell carcinoma).
Why this rating
Financing is material (~45% of market cap), extends runway critically, but carries 12% debt burden and shareholder dependence risk. Advances pipeline milestones but survival-dependent.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.